State-of-the-Art Management of High-Risk Non-Muscle Invasive Bladder Cancer

Early Bladder Recurrence Common in UTUC Patients Post-Nephroureterectomy Despite BCG Treatment - Paul Crispen

July 19, 2024

Details

Advances Bring New Immunotherapy and Targeted Therapy Options for Non-Muscle Invasive Bladder Cancer - Kriti Mittal & Guru Sonpavde

December 19, 2023

Details

Inside the 92nd AUA Meeting: A Deep Dive into High-Risk Non-Muscle Invasive Bladder Cancer - Kriti Mittal

October 13, 2023

Details

The Complex Case of a 46-Year-Old Smoker with High-Grade T1 Bladder Cancer Presentation - Jennifer Yates, Matthew Mossanen, & Kent Mouw

October 13, 2023

Details

In the Wake of BCG Shortages: A Look at Ongoing Clinical Trials and Future Therapies for Bladder Cancer - Jennifer Yates, Lydia Saravis, & Matthew Mossanen

October 13, 2023

Details

The Future of Radiation and Anti-PD-1 Agents in Non-Muscle Invasive Bladder Cancer: An In-Depth Look at Ongoing Trials - Kent Mouw

October 13, 2023

Details

Persistent CIS Despite BCG and Valrubicin: A Case Study in Treatment Challenges - Kriti Mittal

October 13, 2023

Details

A Comprehensive Guide to Managing Immune-Related Adverse Events in Checkpoint Inhibitor Therapy - Laura Wood

October 13, 2023

Details

An Overview of Emerging Agents for Non-Muscle Invasive Bladder Cancer - Guru Sonpavde

October 13, 2023

Details